Saint John’s Cancer Institute is Participating in the BC-IMT-04, Breast Cancer Study

CSMC IRB No: SITE00000115
CSMC Date Effective: 8/26/2024

Randomized, Open-Label Study Of The Bria-IMT Regime And Check Point Inhibitor VS Physician’s Choice In Advanced Metastatic Breast Cancer

BC-IMT-04
NCT ID: 06072612
Phase: 3
Saint John’s Cancer Institute

Saint John’s Cancer Institute is now screening participants for the BriaCell BC-IMT-04 protocol, a study for all patients with advanced breast cancer for whom traditional chemotherapy has failed.

  • A study of the Bria-IMT Regimen and CPI vs Physicians’ Choice in Advanced Metastatic Breast Cancer (BRIA-ABC).
  • A multicenter randomized, open-label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab] versus Treatment of Patients’/Physicians’ Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available. A secondary objective will be to evaluate the activity of the Bria-IMT regimen alone in comparison with the Bria-IMT regimen in combination with CPI.
  • An innovative study uses an injection of a novel agent to stimulate the immune system to attack the cancer in combination with immunotherapy medications.

Please contact 310-582-7448 for screening information.

Learn more at ClinicalTrials.gov:

https://clinicaltrials.gov/study/NCT06072612?term=NCT06072612&rank=1